Alnylam Pharmaceuticals, Inc.
ALNYLast close · Oct 16, 2026231.83−2.20 (−0.94%)
Market cap$31.0B
Between Apr 2, 2026 and Oct 2, 2026, Alnylam Pharmaceuticals (ALNY) insiders filed 40 Form 4 transactions: 16 sales worth $2.1M in total and no open-market purchase; 15 of the sales were under 10b5-1 plans set in advance. The largest seller was Supran Bryan, $398,855. 24 other filings were grants, exercises or gifts, which say nothing about buying or selling.
40
0
16
17
Form 4 transactions
| Date | Insider | Title | Code | Plan | Shares | Price | Value |
|---|---|---|---|---|---|---|---|
| 2026-10-02 | SUPRAN BRYAN | EVP, CLO and Secretary | S | 1,758 | 226.88 | $398,855 | |
| 2026-09-19 | Greenstreet Yvonne | Chief Executive Officer | A | 107 | 0.00 | $0 | |
| 2026-06-01 | PYOTT DAVID E I | Director | M | 10b5-1 | 3,830 | 0.00 | $0 |
| 2026-06-01 | PYOTT DAVID E I | Director | S | 10b5-1 | 921 | 297.71 | $274,190.9 |
| 2026-06-01 | PYOTT DAVID E I | Director | S | 10b5-1 | 1,175 | 298.91 | $351,219.3 |
| 2026-06-01 | PYOTT DAVID E I | Director | S | 10b5-1 | 1,222 | 299.87 | $366,441.1 |
| 2026-06-01 | PYOTT DAVID E I | Director | S | 10b5-1 | 495 | 300.72 | $148,856.4 |
| 2026-06-01 | PYOTT DAVID E I | Director | S | 10b5-1 | 17 | 302.65 | $5,145 |
| 2026-06-01 | PYOTT DAVID E I | Director | M | 10b5-1 | 3,830 | 0.00 | $0 |
| 2026-06-01 | Cravatt Benjamin | Director | A | 4,393 | 0.00 | $0 | |
| 2026-05-20 | Sigal Charles Elliott | Director | A | 671 | 0.00 | $0 | |
| 2026-05-20 | Sigal Charles Elliott | Director | A | 1,441 | 0.00 | $0 | |
| 2026-05-20 | SCHULMAN AMY W | Director | A | 838 | 0.00 | $0 | |
| 2026-05-20 | SCHULMAN AMY W | Director | A | 1,802 | 0.00 | $0 | |
| 2026-05-20 | Reitan Colleen F | Director | A | 671 | 0.00 | $0 | |
| 2026-05-20 | Reitan Colleen F | Director | A | 1,441 | 0.00 | $0 | |
| 2026-05-20 | PYOTT DAVID E I | Director | A | 671 | 0.00 | $0 | |
| 2026-05-20 | PYOTT DAVID E I | Director | A | 1,441 | 0.00 | $0 | |
| 2026-05-20 | KELLOGG PETER N | Director | A | 671 | 0.00 | $0 | |
| 2026-05-20 | KELLOGG PETER N | Director | A | 1,441 | 0.00 | $0 | |
| 2026-05-20 | HAMBURG MARGARET A | Director | A | 671 | 0.00 | $0 | |
| 2026-05-20 | HAMBURG MARGARET A | Director | A | 1,441 | 0.00 | $0 | |
| 2026-05-20 | BRANDICOURT OLIVIER | Director | A | 671 | 0.00 | $0 | |
| 2026-05-20 | BRANDICOURT OLIVIER | Director | A | 1,441 | 0.00 | $0 | |
| 2026-05-20 | Ausiello Dennis A | Director | A | 671 | 0.00 | $0 | |
| 2026-05-20 | Ausiello Dennis A | Director | A | 1,441 | 0.00 | $0 | |
| 2026-05-20 | Arbuckle Stuart A | Director | A | 671 | 0.00 | $0 | |
| 2026-05-20 | Arbuckle Stuart A | Director | A | 1,441 | 0.00 | $0 | |
| 2026-05-13 | SCHULMAN AMY W | Director | M | 11,250 | 70.20 | $789,750 | |
| 2026-05-13 | SCHULMAN AMY W | Director | M | 11,250 | 0.00 | $0 | |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 265 | 316.61 | $83,901.7 |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 359 | 317.44 | $113,961 |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 209 | 318.47 | $66,560.2 |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 86 | 319.69 | $27,493.3 |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 147 | 320.62 | $47,131.1 |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 224 | 321.64 | $72,047.4 |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 245 | 322.86 | $79,100.7 |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 81 | 323.64 | $26,214.8 |
| 2026-04-02 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 8 | 325.49 | $2,603.9 |
| 2026-04-06 | McLaughlin Melissa | Chief Human Resources Officer | S | 10b5-1 | 56 | 320.14 | $17,927.8 |
Codes are the SEC's: P open-market purchase, S open-market sale; M exercise, F tax withholding, A grant and G gift are routine. A 10b5-1 flag means the trade ran under a plan adopted in advance. Method notes in where the numbers come from.